Business
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
British Columbia becomes first Canadian province to provide coverage for TTFields therapy for eligible glioblastoma patients BAAR, Switzerland--(BUSINESS
About this update from Novocure Limited
[{"type":"text","content":"\nBritish Columbia becomes first Canadian province to provide coverage for TTFields therapy for eligible glioblastoma patients\n\n\n BAAR, Switzerland--(BUSINESS WIRE)--\nNovocure (NASDAQ: NVCR) announced today that the province of British Columbia, Canada, will now cover Tumor Treating Fields (TTFields) therapy for the treatment of adult patients with newly diagnosed glioblastoma. British Columbia is the first province to provide coverage following Canada’s Drug Agency’s assessment and reimbursement recommendation for TTFields therapy in glioblastoma.\n\n\n“Glioblastoma is one of the most aggressive cancers, and treatment options for this disease are limited. The newly announced coverage in British Columbia for Tumor Treating Fields therapy means more patients will have access to a treatment option that may potentially extend their survival,” said Lamia Kalfane, Country Manager, Novocure Canada. “We are deeply grateful for the partnership and collaboration of BC Cancer in achieving this milestone. We remain committed to partnering with other provincial healthcare systems to ensure more eligible patients in Canada can equally access TTFields therapy.”\n\n\nPatients with newly diagnosed glioblastoma who meet the treatment criteria established by BC Cancer can receive treatment with TTFields therapy through BC Cancer.\n\n\n“Access to treatment options is a priority when treating aggressive cancers,” said Dr. Justin Oh, Radiation Oncologist, BC Cancer Vancouver. “The addition of Tumor Treating Fields therapy as a covered treatment for eligible patients means we will be able to have more meaningful and robust discussion about available and approved treatment options for this tumor, framed within each patient’s clinical circumstances and personal values.”\n\n\n“When you are up against the relentless progression of brain cancer, a therapy that has met safety and efficacy standards, and has the potential to extend life is profound,” said Anita Angelini, Vice-Chair, Brain Cancer Canada. “Brain Cancer Canada congratulates BC Cancer and Novocure for their work to bring Tumor Treating Fields therapy to patients. Brain Cancer Canada continues to advocate for equitable access to treatment for patients in every province and territory across Canada.”\n\n\nTTFields therapy was approved by Health Canada in 2022 for the treatment of newly diagnos...